Dawaa Reference

chronic

Eye Tumor of Uncertain Behavior

Treatment options, dosing, cautions and Egyptian brands from the shipped Dawaa Reference card.

Evidence status

Checked against the sources named below

Sources3 sources

ICPC-3 (WONCA International Classification of Primary Care, 3rd edition) class FD25.02 - condition scope only, no dose · No dose - referral pathway, no medicine given in primary care · Ocular Melanoma - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK551647/

Verified against1 document
  • No dose - referral pathway, no medicine given in primary care

Verified date2026-08

1

NO DRUG THERAPY IN PRIMARY CARE (RECOGNITION & REFERRAL)

1st line
Adult dose and duration

A growth of the eye whose behaviour - benign versus malignant - is not yet determined; a GP refers for biopsy and specialist evaluation. - Refer

Paediatric dose

Children follow the same pathway: recognise and refer. No primary-care medicine is implied.

Dose source

No dose - referral pathway, no medicine given in primary care

Why

A growth of the eye whose behaviour - benign versus malignant - is not yet determined; a GP refers for biopsy and specialist evaluation.

Cautions
  • Rare in Egyptian primary care.
  • No medicine is prescribed for this in primary care - this entry is for recognition and referral. Anything given is decided by the service it is referred to.
  • RED FLAG - Any suspicious growth or change in size; expedite biopsy or specialist referral.

Prices are indicative (dataset snapshot 2026-06); verify with the pharmacy.